Showing results (71-80 of 157) with videos related to

Sort By:
Pageof 16
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2020
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|March 14, 2013
Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung CANCERZhi-Jie Wang, Tong-Tong An, Tony Mok, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancerYing Cheng, Qing Zhou, Baohui Han, et al.
The Oncologist|May 27, 2018
Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal CancerStephen L Chan, Anthony W H Chan, Frankie Mo, et al.
The Lancet. Oncology|December 3, 2014
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trialPasi A Jänne, Sai-Hong I Ou, Dong-Wan Kim, et al.
The New England Journal of Medicine|November 18, 2020
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung CancerAlice T Shaw, Todd M Bauer, Filippo de Marinis, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancerTony Mok, Guia Ladrera, Vichien Srimuninnimit, et al.
The New England Journal of Medicine|December 4, 2014
First-line crizotinib versus chemotherapy in ALK-positive lung cancerBenjamin J Solomon, Tony Mok, Dong-Wan Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2022
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancerJulien Mazieres, Laura Iadeluca, Alice T Shaw, et al.
Future Oncology (London, England)|September 29, 2021
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancerBenjamin J Solomon, Todd M Bauer, Filippo de Marinis, et al.
Pageof 16